New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 17, 2014
08:13 EDTMRTXMirati Therapeutic' mocetinostat granted ODD by FDA as treatment for MDS
Mirati Therapeutics announced that mocetinostat, the company's spectrum selective HDAC inhibitor, has been granted Orphan Drug Designation, or ODD, by the FDA as a treatment for myelodysplastic syndrome, or MDS. Mocetinostat is being developed in Phase 2 clinical studies in combination with Vidaza as a treatment for intermediate and high-risk MDS, as well as a single agent treatment in patients with diffuse large B-cell lymphoma and bladder cancer targeting specific genetic mutations in histone acetylation that increase the likelihood of response in tumor cells.
News For MRTX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 23, 2015
14:38 EDTMRTXMirati Therapeutics to present data on MGCD265, MGCD516 cancer drugs
Mirati Therapeutics announced it will present data on its two tyrosine kinase inhibitors, MGCD265 and MGCD516, at the International Association of Lung Cancer 16th World Conference on Lung Cancer being held September 6-9. The titles of the two oral presentations are "Evaluation of the MET/Axl Receptor Tyrosine Kinase Inhibitor MGCD265 in a Patient with Metastatic Non-Small Cell Lung Cancer Harboring Axl Amplification" and "In Vitro and In Vivo Evaluation of the Kinase Inhibitor, MGCD516, in Trk and RET Fusion Cancer Cells."

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use